Epigenetic aging during childhood can predict cardiometabolic health in young adulthood and indicate increased risk for cardiometabolic disease.
J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback